JERUSALEM--(BUSINESS WIRE)--Oct. 15, 2015--
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it
will host a conference call and live webcast along with a slide
presentation on Thursday, October 29, 2015 at 8 a.m. ET to communicate
its third quarter 2015 financial results. A question & answer session
will follow.
In order to participate, please dial the following numbers (at least 10
minutes before the scheduled start time): United States 1-866-331-1383;
Canada 1-877-216-6951 or International +44(0) 145 2322581; passcode:
55277282. For a list of other international toll-free numbers, click here.
A live webcast of the call will also be available on Teva's website at: www.ir.tevapharm.com.
Please log in at least 10 minutes prior to the conference call in order
to download the applicable audio software.
Following the conclusion of the call, a replay of the webcast will be
available within 24 hours on the Company's website. The replay can also
be accessed until November 29, 2015, 10:00 a.m. ET by calling United
States 1-866-247-4222; Canada 1-866-878-9237 or International +44(0) 145
2550000; passcode: 55277282.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading
global pharmaceutical company that delivers high-quality,
patient-centric healthcare solutions to millions of patients every day.
Headquartered in Israel, Teva is the world’s largest generic medicines
producer, leveraging its portfolio of more than 1,000 molecules to
produce a wide range of generic products in nearly every therapeutic
area. In specialty medicines, Teva has a world-leading position in
innovative treatments for disorders of the central nervous system,
including pain, as well as a strong portfolio of respiratory products.
Teva integrates its generics and specialty capabilities in its global
research and development division to create new ways of addressing unmet
patient needs by combining drug development capabilities with devices,
services and technologies. Teva's net revenues in 2014 amounted to $20.3
billion. For more information, visit www.tevapharm.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151015005957/en/
Source: Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
IR:
Kevin C.
Mannix
United States
215-591-8912
or
Ran Meir
United
States
215-591-3033
or
Tomer Amitai
Israel
972
(3) 926-7656
or
PR:
Iris Beck Codner
Israel
972
(3) 926-7246
or
Denise Bradley
United States
215-591-8974